Gd-DOTA administration at MRI in children younger than 18 months of age: Immediate adverse reactions

Pediatric Radiology

Volumn 41, Issue 11, 2011, Pages 1401-1406

  Emond, Sophie ^a   Brunelle, Francis ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Gd DOTA; Infant; Neonate; Safety

Indexed keywords

GADOTERATE MEGLUMINE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CONTRAST ENHANCEMENT; DRUG SAFETY; FEMALE; HUMAN; IMAGE QUALITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL;

CONTRAST MEDIA; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; MALE; ORGANOMETALLIC COMPOUNDS; QUESTIONNAIRES;

EID: 80755146141     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-011-2167-3     Document Type: Article

References (24)

1. C Burtea S Laurent L Vander Elst RN Muller 2008 Contrast agents: magnetic resonance Handb Exp Pharmacol 185 135 165 18626802 10.1007/978-3-540-72718-7-7 1:CAS:528:DC%2BD1MXhs1Squ7s%3D
2. S Hanquinet C Christophe DD Greef P Gordon N Perlmutter 1996 Clinical evaluation of gadodiamide injection in paediatric MR imaging Pediatr Radiol 26 11 806 810 8929382 10.1007/BF01396206 1:STN:280:DyaK2s%2FnsVamsg%3D%3D (Pubitemid 26383703)
3. EA Sadowski LK Bennett MR Chan, et al. 2007 Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 148 157 17267695 10.1148/radiol.2431062144 (Pubitemid 46579705)
4. T Grobner 2006 Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 1104 1108 16431890 10.1093/ndt/gfk062 1:CAS:528: DC%2BD28XivVOntb8%3D
5. E Altun RC Semelka C Cakit 2009 Nephrogenic systemic fibrosis and management of high-risk patients Acad Radiol 16 897 905 19375360 10.1016/j.acra.2009.01.001
6. N Janus V Launay-Vacher S Karie, et al. 2010 Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the finest study Eur J Radiol 73 357 359 19128909 10.1016/j.ejrad.2008.11.021
7. IA Mendichovszky SD Marks CM Simcock OE Olsen 2008 Gadolinium and nephrogenic systemic fibrosis: time to tighten practice Pediatr Radiol 38 5 489 496 17943276 10.1007/s00247-007-0633-8 (Pubitemid 351501690)
8. SK Morcos 2008 Extracellular gadolinium contrast agents: differences in stability Eur J Radiol 66 2 175 179 18343072 10.1016/j.ejrad.2008.01.025 1:STN:280:DC%2BD1c3ntlertg%3D%3D
9. CM Herve-Somma GH Sebag AM Prieur V Bonnerot DP Lallemand 1992 Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA Radiology 182 1 93 98 1727317 1:STN:280:DyaK38%2FotVOguw%3D%3D
10. V Bonnerot G Sebag M de Montalembert, et al. 1994 Gadolinium-DOTA enhanced MRI of painful osseous crises in children with sickle cell anemia Pediatr Radiol 24 2 92 95 8078730 10.1007/BF02020160 1:STN:280: DyaK2czlvFOltg%3D%3D (Pubitemid 24166917)
11. H Ducou le Pointe S Haddad B Silberman G Filipe M Monroc JP Montagne 1994 Legg-Perthes-Calve disease: staging by MRI using gadolinium Pediatr Radiol 24 2 88 91 8078729 10.1007/BF02020159 1:STN:280:DyaK2czlvFOlsQ%3D%3D (Pubitemid 24166916)
12. R Hermans 2006 Head and neck cancer: how imaging predicts treatment outcome Cancer Imaging 6 S145 153 17114069 10.1102/1470-7330.2006.9028
13. WC Hsu LA Loevner R Karpati, et al. 2005 Accuracy of magnetic resonance imaging in predicting absence of fixation of head and neck cancer to the prevertebral space Head Neck 27 2 95 100 15627263 10.1002/hed.20128 (Pubitemid 40194684)
14. U Bartels M Shroff L Sung, et al. 2006 Role of spinal MRI in the follow-up of children treated for medulloblastoma Cancer 107 6 1340 1347 16894528 10.1002/cncr.22129 (Pubitemid 44452784)
15. S Kobayashi K Hayakawa T Nakane, et al. 2009 Visualization of intraneural edema using gadolinium-enhanced magnetic resonance imaging of carpal tunnel syndrome J Orthop Sci 14 1 24 34 19214684 10.1007/s00776-008-1291-x
16. JL Drape P Thelen P Gay-Depassier O Silbermann R Benacerraf 1993 Intraarticular diffusion of Gd-DOTA after intravenous injection in the knee: MR imaging evaluation Radiology 188 1 227 234 8511303 1:STN:280: DyaK3s3ovVyrsg%3D%3D (Pubitemid 23183129)
17. WA Willinek HH Schild 2008 Clinical advantages of 3.0 T MRI over 1.5 T Eur J Radiol 65 1 2 14 18162354 10.1016/j.ejrad.2007.11.006
18. M Riccabona J Simbrunner E Ring, et al. 2002 Feasibility of MR urography in neonates and infants with anomalies of the upper urinary tract Eur Radiol 12 1442 1450 12042952 10.1007/s00330-001-1180-6 1:STN:280:DC%2BD38zgtFSruw%3D%3D (Pubitemid 36940221)
19. CU Herborn E Honold M Wolf, et al. 2007 Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA) Invest Radiol 42 1 58 62 17213750 10.1097/01.rli.0000248893.01067.e5 1:CAS:528: DC%2BD2sXpslWgug%3D%3D (Pubitemid 46072553)
20. Briand Y, Neiss AC, Vitry A (1992) Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multi-centre study. In: 29th congress of the European Society of Pediatric Radiology, Budapest: R12.
21. FG Shellock JR Parker G Pirovano, et al. 2006 Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine J Magn Reson Imaging 24 1378 1385 17078095 10.1002/jmri.20764 (Pubitemid 44871885)
22. PH Kuo E Kanal AK Abu-Alfa, et al. 2007 Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis Radiology 242 647 649 17213364 10.1148/radiol.2423061640
23. T Grobner 2008 Prischl FC (2008) Patient characteristics and risk factors for nephrogenic systemic fibrosis for gadolinium exposure Semin Dial 21 135 139 18226001 10.1111/j.1525-139X.2007.00406.x
24. JM Idee M Port A Dencausse E Lancelot C Corot 2009 Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update Radiol Clin N Am 47 5 855 869 19744600 10.1016/j.rcl.2009.06.006